checkAd

Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone Lispro Formulation Containing Insulin from Partner Tonghua Dongbao - Seite 2

Nachrichtenquelle: Business Wire (engl.)
25.01.2021, 18:00  |  204   |   |   

All four interventions were safe and well tolerated.

These results confirm the ultra-rapid insulin action profile of BC Lispro, and a safety profile similar to that of Humalog. This study was approved by the German Health Authority on the 24th of July 2020, as well as by the FDA on the 29th of July 2020 as part of an IND study.

This is a very important step for Adocia as we now feature a product ready for Phase 3 studies worldwide. Moreover, it is a product supported by a global supply agreement for high quality lispro drug substance from our partner Tonghua Dongbao. Our priority remains to find a partner to lead the Phase 3 program for Europe and the United States", comments Olivier Soula, the Deputy CEO and Director of R&D at Adocia.

About BioChaperone Lispro

BioChaperone Lispro (BC Lispro) is an ultra-rapid prandial insulin formulation containing insulin lispro and the proprietary technology BioChaperone. The BioChaperone excipient ensures a faster absorption of insulin. BC Lispro has demonstrated a faster action profile compared to insulin analog lispro (Humalog, Eli Lilly) and insulin analog aspart (Novolog, Novo Nordisk), in nine Phase 1/2 studies in people with type 1 and type 2 diabetes, administered either by syringes or insulin pumps. Also, BC Lispro significantly improved insulin performance compared to Humalog in six clinical studies.

In 2018, Adocia and partner Tonghua Dongbao (China) signed a strategic alliance to develop and commercialize BC Lispro in China and in other Asian and Middle East territories. Tonghua Dongbao also supplies insulin lispro and insulin glargine to Adocia for the entire world (except China). This supply allows Adocia to progress its own BC Lispro and BC Combo programs and expand its partnership opportunities. Adocia retains development rights for BC Lispro in the US, Europe, Japan and Latin America. BC Lispro is ready for out-licensing in these key territories.

For more information on BC Lispro, visit our website: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin ...

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring four clinical-stage products. The proprietary BioChaperone technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.

Seite 2 von 3
ADOCIA Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone Lispro Formulation Containing Insulin from Partner Tonghua Dongbao - Seite 2 Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC, the “Company”), the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel